Exploring where Designers and Non-Designers meet within the Service Organisation: Considering the value designers bring to the service design process

Service design is sometimes thought of as the interface between the customer and the service provider, a design process that exists between design thinking and business practices. Service design consultancies working with service organisations are increasingly attempting to develop design thinking alongside business processes within the organisation, but if everyone becomes a ‘designer’ what value is placed on the design-trained service designer? What qualities, knowledge and skills does a designer offer that identifies them as a valuable business asset who has an integral place within the business process, rather than as someone brought in when the organisation wants to be seen to be ‘creative’ or ‘innovative.’ The process of design for services is well documented, however there is not much debate around whether the service designer needs to be design-trained, or of what benefits they would offer if they were. It is assumed that design tools and methods can be introduced and disseminated to non-designers, but if tools and methods are all it took to design services, what is the future for the ‘designer?’ From observations of students studying service design at postgraduate level and a comparative study with design and non-design staff within a service organisation, this paper aims to uncover the value and ‘craft’ of the designer within the context of the service design process

Embedding service design: the long and the short of it. Developing an organisation's design capacity and capability to sustainably deliver services

Abstract What are the factors affecting how service design methods and practices are embedded within an organisation? How can embedding of design methods be done sustainably, providing lasting benefits? Over a four-year period, the author observed and studied a large public sector organisation as it developed in-house service design capabilities and strove to embed design thinking and processes within its business culture and working practices. The conditions necessary to enable innovation to take place within an organisation are not so dissimilar to those observed for embedding design, and for enabling design to be used effectively in the development and delivery of services. As with any innovation, the introduction of the practice of service design within an organisation requires a change in culture and behaviour: in this case, a shift in focus from the mechanics of delivery to include the experience of the customer. The in-house service designer is required to juggle long-term delivery of business strategy while creating short-term value to the business through project outcomes. A balance must be struck between the dissemination of design methods and processes within the organisation while keeping an eye on the long-term business strategy. The eventual goal being to effectively modify the organisational DNA of service delivery, where design methods are sustainably applied at various levels throughout the organisation

Reduced axonal diameter of peripheral nerve fibres in a mouse model of Rett syndrome

Rett syndrome (RTT) is a neurological disorder characterized by motor and cognitive impairment, autonomic dysfunction and a loss of purposeful hand skills. In the majority of cases, typical RTT is caused by de novo mutations in the X-linked gene, MECP2. Alterations in the structure and function of neurons within the central nervous system of RTT patients and Mecp2-null mouse models are well established. In contrast, few studies have investigated the effects of MeCP2-deficiency on peripheral nerves. In this study, we conducted detailed morphometric as well as functional analysis of the sciatic nerves of symptomatic adult female Mecp2+/- mice. We observed a significant reduction in the mean diameter of myelinated nerve fibers in Mecp2+/- mice. In myelinated fibers, mitochondrial densities per unit area of axoplasm were significantly altered in Mecp2+/- mice. However, conduction properties of the sciatic nerve of Mecp2 knockout mice were not different from control. These subtle changes in myelinated peripheral nerve fibers in heterozygous Mecp2 knockout mice could potentially explain some RTT phenotypes

Thinking about growth : a cognitive mapping approach to understanding small business development

School of Managemen

Status of the LBNL normal-conducting CW VHF electron photo-gun

The fabrication and installation at the Lawrence Berkeley National Laboratory of a high-brightness high-repetition rate photo-gun, based on a normal conducting 187 MHz (VHF) RF cavity operating in CW mode, is in an advanced phase. The cavity will generate an electric field at the cathode plane of ∼ 20 MV/m to accelerate the electron bunches up to ∼ 750 keV, with peak current, energy spread and transverse emittance suitable for FEL and ERL applications. The gun vacuum system has been designed for achieving pressures compatible with the use of "delicate" high quantum efficiency semiconductor cathodes to generate up to a nC bunches at MHz repetition rate with present laser technology. Several photo-cathode/laser systems are under consideration, and in particular photo-cathodes based on K CsSb are being developed for the gun and have already achieved a QE of 8% at 532 nm wavelength, or close to 20% including the Schottky barrier lowering. The cathode will be operated by a μJ fiber laser in conjunction with refractive transverse beam shaping to create a flat top transverse profile, as well as a birefringent pulse stacker to create a flat top temporal profile. The present status and the plan for future activities are presented.

Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome

Rett syndrome (RTT), caused by loss-of-function mutations in the MECP2 gene, is a neurological disorder characterized by severe impairment of motor and cognitive functions. The aim of this study was to investigate the impact of vector design, dosage and delivery route on the efficacy and safety of gene augmentation therapy in mouse models of RTT. Our results show that AAV-mediated delivery of MECP2 to Mecp2-null mice by systemic administration, and utilizing a minimal endogenous promoter, was associated with a narrow therapeutic window and resulted in liver toxicity at higher doses. Lower doses of this vector significantly extended survival of mice lacking MeCP2 or expressing a mutant T158M allele but had no impact on RTT-like neurological phenotypes. Modifying vector design by incorporating an extended Mecp2 promoter and additional regulatory 3’-UTR elements significantly reduced hepatic toxicity after systemic administration. Moreover, direct cerebroventricular injection of this vector into neonatal Mecp2-null mice resulted in high brain transduction efficiency, increased survival and bodyweight and an amelioration of RTT-like phenotypes. Our results show that controlling levels of MeCP2 expression in the liver is achievable through modification of the expression cassette. However, it also highlights the importance of achieving high brain transduction to impact the RTT-like phenotypes

Author Correction: Cross-ancestry genome-wide association analysis of corneal thickness strengthens link between complex and Mendelian eye diseases.

Emmanuelle Souzeau, who contributed to analysis of data, was inadvertently omitted from the author list in the originally published version of this Article. This has now been corrected in both the PDF and HTML versions of the Article

Assessing free-living physical activity using accelerometry : practical issues for researchers and practitioners

Physical activity is an integral component of a healthy lifestyle, with relationships documented between physical activity, chronic diseases, and disease risk factors. There is increasing concern that many people are not sufficiently active to benefit their health. Consequently, there is a need to determine the prevalence of physical activity engagement, identify active and inactive segments of the population, and evaluate the effectiveness of interventions. The aim of the present study was to identify and explain a number of methodological and decision-making processes associated with accelerometry, which is the most commonly used objective measure of physical activity in child and adult research.Specifically, this review addresses:(a) pre-data collection decisions,(b) data collection procedures,(c) processing of accelerometer data, and(d) outcome variables in relation to the research questions posed.An appraisal of the literature is provided to help researchers and practitioners begin field-based research, with recommendations offered for best practice. In addition, issues that require further investigation are identified and discussed to inform researchers and practitioners of the surrounding debates.Overall, the review is intended as a starting point for field-based physical activity research using accelerometers and as an introduction to key issues that should be considered and are likely to be encountered at this time.<br /

Smoking Cessation Intervention for Severe Mental Ill Health Trial (SCIMITAR+) : study protocol for a randomised controlled trial

BACKGROUND: Smoking is highly prevalent among people who have experience of severe mental ill health, contributing to their poor physical health. Despite the 'culture' of smoking in mental health services, people with severe mental ill health often express a desire to quit smoking; however, the services currently available to aid quitting are those which are widely available to the general population and may not be suitable or effective for people with severe mental ill health. The aim of this study is to explore the effectiveness and cost-effectiveness of a bespoke smoking-cessation intervention specifically targeted at people with severe mental ill health. METHODS/DESIGN: SCIMITAR+ is a multicentre, pragmatic, two-arm, parallel-group, individually randomised controlled trial. We aim to recruit 400 participants aged 18 years and above with a documented diagnosis of bipolar disorder, schizophrenia or schizoaffective disorder who smoke. Potentially eligible participants identified in primary or secondary care will be screened, and baseline data collected. Eligible, consenting participants will be randomly allocated to one of two groups. In the intervention arm, the participant will be assigned a mental health professional trained to deliver smoking-cessation interventions who will work with the participant and participant's GP or mental health specialist to provide an individually tailored smoking-cessation service. The comparator arm will be usual care - following current NICE guidelines for smoking cessation, in line with general guidance that is offered to all smokers, with no specific adaptation or enhancement in relation to severe mental ill health. The primary outcome will be self-reported smoking cessation at 12 months verified by expired carbon monoxide (CO) measurement. Secondary outcome measures include Body Mass Index at 12 months, the Fagerström Test for Nicotine Dependence, Motivation to Quit questionnaire, SF-12, PHQ-9, GAD-7, EQ-5D-5 L, and health service utilisation at 6 and 12 months. The economic evaluation at 12 months will be conducted in the form of an incremental cost-effectiveness analysis. DISCUSSION: SCIMITAR+ trial is the largest trial to our knowledge to investigate the effectiveness of a bespoke smoking-cessation service for people with severe mental ill health. TRIAL REGISTRATION: International Standard Randomised Controlled Trials Number, ISRCTN72955454 . Registered on 16 January 2015